It's the penultimate weekend of the 2024 season, and five more teams can punch their playoff tickets. Others can cement their spots on the playoff tree. Either way, we're two weeks away from the ...

In Week 16, Simms chopped my lead in half. I’m now up by only two games, with two weeks to go. I’m 164-76 and he’s 162-78, after I went 9-7 and he went 11-5. Against the spread, it’s been over for a ...

Gunnar Esiason isn't like most hockey players -- his ability to complete a shift often depended on how his cystic fibrosis was affecting him that day. Throughout his journey with CF, hockey became ...

Gunnar Esiason isn't like most hockey players -- his ability to complete a shift often depended on how his cystic fibrosis was affecting him that day. Throughout his journey with CF, hockey became a ...

1. Chiefs (last week No. 3; 14-1): The Chiefs are inevitable. 2. Bills (No. 2; 12-3): Can the defense hold up in the playoffs? 3. Vikings (No. 4; 13-2): They’re the most overlooked 13-2 team the NFL ...

As Vertex Pharmaceuticals reels from a painful trial readout for its pain candidate suzetrigine, the Boston biotech has chalked up a win in its specialty area of cystic fibrosis. The FDA has ...

Cystic fibrosis (CF) is a genetic condition that leads to the production of thick, sticky mucus, which can cause complications in multiple organs, including the sinuses, lungs, intestines ...

It’s welcome good news for Vertex following last week’s subpar clinical results for its non-opioid analgesic. Vertex Pharmaceuticals said Friday the FDA has approved its next cystic fibrosis product ...

Nearly sixteen full weeks into the season, and much has been decided. Plenty remains TBD. In the NFC, the top seed is basically down to two teams in the same division, the Lions and the Vikings.

A new CFTR modulator treatment called Alyftrek has been approved for people with CF ages 6 and older who have CFTR mutations that are eligible for Trikafta, as well as 31 other rare mutations that ...

The U.S. Food and Drug Administration (FDA) today approved the expansion of Trikafta (elexacaftor/tezacaftor/ivacaftor) to people with cystic fibrosis ages 2 and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...